MannKind Corporation (NASDAQ: MNKD) has been a very interesting stock to watch since 2014, when the United States Food and Drug Administration (FDA) approved the company’s inhaled insulin known as Afrezza. Considering that there were no needles to be used and the insulin was a fast-acting, after-meals option, investors believed that the treatment would fly off of the shelves. However, that’s not exactly what happened.
The commercialization phase started with an agreement with Sanofi SA (ADR) (NYSE: SNY). However, after about a year under contract, sales weren’t going anywhere. As a result, SNY and MNKD terminated the agreement, giving the rights to commercialization back to MNKD. While many believed that this would lead to an increase in sales, that wasn’t the case. Nonetheless, many believe that with the stock trading at well under $3.00 per share, there is an opportunity for long-run gains. But is there? Today, we’ll talk about:
- the technology that made Afrezza possible;
- Afrezza sales;
- a current trial for a new treatment;
- the risks involved in MNKD;
- and whether or not now is the time to consider an investment in the company.
Technosphere Is The Secret Behind Afrezza
Afrezza is the first insulin on the market that can be inhaled rather than injected. The technology that made Afrezza possible is known as Technosphere, a proprietary dry powder designed by MannKind. Technosphere is a dry powder that’s designed to be a delivery method for medications that could otherwise only be injected. Instead, the dry powder can be inhaled and has the ability to deliver treatments in a more rapid way directly through the lungs.
Ultimately, there are several advantages that come as a result of Technosphere by MNKD. First and foremost, the powder can be used with a wide variety of medications, making the implications of this technology wide-ranging. Also, because of how the powder is delivered, it allows for rapid absorption of the medication being delivered through this vehicle. Not to mention, this avoids the instance of hepatic metabolism, an adverse event seen with various treatments. This, combined with technosphere’s excellent bioavailability and the fact that it is delivered through an inhaler rather than an invasive and (for many) scary needle, makes this technology a key breakthrough in the medical space.